Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
DINARDO, COURTNEY
One or more keywords matched the following items that are connected to DINARDO, COURTNEY
Item TypeName
Concept Isocitrate Dehydrogenase
Academic Article Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.
Academic Article Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents.
Academic Article Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML.
Academic Article Targeting Isocitrate Dehydrogenase (IDH) in cancer
Academic Article Isocitrate dehydrogenase mutations in myeloid malignancies
Academic Article Targeting isocitrate dehydrogenase (IDH) in cancer.
Academic Article Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.
Academic Article Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes.
Academic Article Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.
Academic Article Novel Therapeutics in Acute Myeloid Leukemia.
Academic Article Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia.
Academic Article The role of IDH mutations in acute myeloid leukemia.
Academic Article Enasidenib for patients with relapsed acute myeloid leukemia and the IDH2 mutation.
Academic Article Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.
Academic Article Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.
Academic Article Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms.
Academic Article Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
Academic Article Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia.
Academic Article Ivosidenib in IDH1-Mutated Acute Myeloid Leukemia.
Academic Article SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML.
Academic Article Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.
Academic Article Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.
Academic Article Acute Myeloid Leukemia: from Mutation Profiling to Treatment Decisions.
Academic Article How I treat acute myeloid leukemia in the era of new drugs.
Academic Article Single-agent and combination biologics in acute myeloid leukemia.
Academic Article Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
Academic Article Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial.
Academic Article Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation.
Academic Article Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML.
Academic Article Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results.
Academic Article Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
Academic Article Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors.
Academic Article Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
Academic Article Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia.
Academic Article Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia.
Academic Article Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia.
Academic Article Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant.
Academic Article Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia.
Academic Article Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia.
Academic Article Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm.
Academic Article Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
Academic Article A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome.
Academic Article Combining Isocitrate Dehydrogenase Inhibitors With Existing Regimens in Acute Myeloid Leukemia: An Evolving Treatment Landscape.
Academic Article Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.
Academic Article Impact of Venetoclax and Azacitidine in Treatment-Na?ve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations.
Academic Article Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.
Academic Article Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome.
Academic Article Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment.
Academic Article A Phase Ib/II Study of Ivosidenib with Venetoclax ? Azacitidine in IDH1-Mutated Myeloid Malignancies.
Academic Article IDH2 mutations in acute myeloid leukemia.
Academic Article Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents.
Search Criteria
  • Isocitrate Dehydrogenase